CONFERENCE PROGRAM AND SCHEDULE

THURSDAY	, NOVEMBER 15	10:45-11:20	Opening Keynote Lecture Precision medicine in lung cancer: Opportunities and challenges
07:30-08:30	Breakfast Crystal Ballroom Foyer		Waun Ki Hong, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
08:30-10:10	Educational Session: Genomics-Driven Clinical Trials	11:20-13:00	Luncheon Symposia and Special Lecture Sessions will be held simultaneously
	Crystal Ballroom Session Cochairs: Yoon-Koo Kang, University of Ulsan College of Medicine, Seoul, Korea, and Elaine R. Mardis,	11:20-11:50	Luncheon Symposium 1 Crystal Ballroom Presented by ONO Pharma Korea / Bristol- Myers Squibb
	Nationwide Children's Hospital, Columbus, OH, USA		Session Chair: Geon Kook Lee, National Cancer Center, Goyang, Korea
08:30-08:55	Precision medicine in lung cancer: Prime time Myung-Ju Ahn, Sungkyunkwan University Samsung Medical Center, Seoul, Korea		Tumor mutational burden as a predictive biomarker in immuno-oncology: Implications for clinical practice and worldwide implementation Aurora Seminara, Bristol-Myers Squibb,
08:55-09:20	The Umbrella Trial in GC: Understanding the disease through genomics		Princeton, NJ, USA
	Jeeyun Lee, Sungkyunkwan University Samsung Medical Center, Seoul, Korea	11:20-12:00	Luncheon Symposium 2 Emerald Room Presented by AstraZeneca
09:20-09:45	Tumor agnostic drug development: Revisiting the scorecard in 2018 Alexander E. Drilon, Memorial Sloan Kettering Cancer Center, New York, NY, USA		Session Chair: Sang-We Kim, University of Ulsan College of Medicine, Seoul, Korea
09:45-10:10	Overview of genomic technologies Elaine R. Mardis		Optimal strategy to manage T790M mutant NSCLC patients: from diagnosis to treatment Hye Ryun Kim, Yonsei University College of Medicine, Seoul, Korea
10:10-10:30	Break	11:20-12:00	Luncheon Symposium 3 Sapphire Ballroom A Presented by Merck Korea
10:30-11:20	Welcome and Opening Keynote Lecture Crystal Ballroom		Session Chair: Young Suk Park, Samsung Medical Center, Seoul, Korea
10:30-10:40	Welcome Tae-You Kim, Seoul National University Hospital, Seoul, Korea		Optimized treatment strategy in RASwt mCRC with recent precision medicine Myung Ah Lee, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea
	Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA		
10:40-10:45	Introduction Charles L. Sawyers		

12:00-13:00	Special Lecture 1: "Scientia potentia est"— NGS-based precision medicine Crystal Ballroom	14:40-15:00	Break
	Session Chair: Yeul Hong Kim, Korea University College of Medicine, Seoul, Korea	15:00-16:40	Plenary Session 2: Precision Diagnostics: NGS-Based Cancer Panels Crystal Ballroom
12:00-12:15	K-MASTER Program overview: Korean Precision Medicine Initiative Yeul Hong Kim, Korea University College of Medicine, Seoul, Korea		Session Cochairs: Eun Sook Lee, National Cancer Center Korea, Goyang, Korea, and Thomas D. Brown, Swedish Cancer Institute, Seattle, WA, USA
12:15-12:30	QuIP TMB technical comparability study: The German approach Jörg Maas, Qualitätssicherungs-Initiative Pathologie, Berlin, Germany	15:00-15:25	Current status of the Korean Cancer Precision Medicine Project, K-Master Yeul Hong Kim, Korea University College of Medicine, Seoul, Korea
12:30-13:00	Discussion and Q&A: Regulatory considerations for NGS oncopanel development Panelists: Yeul Hong Kim, Geon Kook Lee, Jörg Maas, and Aurora Seminara	15:25-15:50	Impact of clinical NGS: Lessons from lung cancer Jessica Jiyeong Lin, Massachusetts General Hospital Cancer Center, Boston, MA, USA
13:00-14:40	Plenary Session 1: Cancer Genomics Crystal Ballroom Session Cochairs: Hyun Cheol Chung,	15:50-16:15	Updated results and new studies in the nationwide NGS-based new agent development Atsushi Ohtsu, National Cancer Center Hospital East, Chiba, Japan
	Yonsei University College of Medicine, Seoul, Korea, and Patrick Tan, Duke-NUS Medical School, Singapore	16:15-16:40	The future of cancer care through biologic profiling and big data Thomas D. Brown
13:00-13:25	Knowledge to practice using cancer genomics Se-Hoon Lee, Samsung Medical Center, Seoul, Korea	16:40-17:10	Spotlight on Proffered Papers Session 1 Crystal Ballroom
13:25-13:50	Genomic and epigenomic profiles of Asian gastrointestinal malignancies Patrick Tan		Session Cochairs: Tae Won Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, and Jessica Jiyeong Lin, Massachusetts General
13:50-14:15	Identification of genomic features that can predict the response to chemotherapy using patient-derived xenograft models Jong-II Kim, Seoul National University College of Medicine, Seoul, Korea	16:40-16:50	Hospital Cancer Center, Boston, MA, USA Targeted sequencing analysis of pulmonary adenocarcinoma with multiple synchronous ground-glass/lepidic nodules*
14:15-14:40	Implementing cancer genomics into the diagnosis and treatment of pediatric cancer		Eunhyang Park, Seoul National University Bundang Hospital, Seoul National University College Of Medicine, Seongnam, Korea
	Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH, USA	16:50-17:00	Mechanisms of gene fusion formation in bone and soft tissue tumors* Nathaniel Anderson, The Hospital for Sick Children, Toronto, ON, Canada

^{*}Short talk from proffered abstract

CONFERENCE PROGRAM AND SCHEDULE

17:00-17:10	TET1-mediated 5-hydroxymethylcytosine alteration in the pathogenesis of	10:40-11:20	Keynote Lecture Crystal Ballroom
	medulloblastoma* Hyerim Kim, Emory University, Atlanta, GA, USA	10:40-10:45	Introduction Tae-You Kim, Seoul National University Hospital, Seoul, Korea
17:15-19:30	Poster Session A and Reception Sapphire Ballroom B	10:45-11:20	Clinical trials in the era of precision medicine Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Korea
FRIDAY, NO	OVEMBER 16	11:20-13:00	Luncheon Symposia and Special Lecture Sessions will be held simultaneously
07:30-08:30	Breakfast	11:20-12:00	Luncheon Symposium 4 Crystal Ballroom Presented by Roche Korea
	Crystal Ballroom Foyer		Session Chair: Ki Hyeong Lee, Chungbuk National University College of Medicine, Cheongju, Korea
08:30-10:10	Plenary Session 3: Liquid Biopsy Crystal Ballroom		Targeting VEGF in the era of cancer
	Session Cochairs: Tae-You Kim, Seoul National University Hospital, Seoul, Korea, and Ryan Dittamore, Epic Sciences, San		immunotherapy Ji-Youn Han, National Cancer Center, Goyang, Korea
	Diego, CA, USA	11:20-12:00	Luncheon Symposium 5 Emerald Room
08:30-08:55	Monitoring treatment response and progression in cancer patients with		Presented by Amgen Korea
	circulating tumor DNA sequencing Woong-Yang Park, Samsung Genome Institute, Seoul, Korea		Session Chair: Jin Seok Ahn, Samsung Medical Center, Seoul, Korea
08:55-09:20	Clinical validation of single CTC profiling as a predictive biomarker of treatment selection in mCRPC Ryan Dittamore		RANKL inhibition as a treatment option in preventing skeletal-related events in cancer patients with bone metastases Alison T. Stopeck, University of Arizona Cancer Center, Tucson, AZ, USA
09:20-09:45	Technology perspectives of liquid biopsy Duhee Bang, Yonsei University, Seoul, Korea	11:20-12:00	Luncheon Symposium 6 Sapphire Ballroom A
09:45-10:10	Plasma circulating tumor DNA predicts therapy outcomes in advanced prostate cancer Alexander W. Wyatt, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada		Presented by Sanofi Genzyme Session Chair: Jong Gwang Kim, Kyungpook National University School of Medicine, Daegu, Korea Expanding the horizons in treatment of mCRC: How to choose the "right" second line
10:10-10:40	Break		Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan

^{*}Short talk from proffered abstract

12:10-13:00	Special Lecture 2 Crystal Ballroom Session Chair: Jin-Hyoung Kang, College of	15:00-15:25	Effective biomarker for immune-precision treatment of metastatic gastric cancer Sun Young Rha, Yonsei University College of Madicine County Konne
	Medicine, The Catholic University of Korea, Seoul, Korea Building a clinico-genomic database to	15:25-15:50	Medicine, Seoul, Korea Comparative analysis of tumor-infiltrating T cells across multiple tumor indications Zemin Zhang
	inform cancer immunotherapy treatment Geoff Otto, Foundation Medicine, Cambridge, MA, USA	15:50-16:15	Advancement in anti-PD-1 therapy: Prediction and combination Eui-Cheol Shin, KAIST, Daejeon, Korea
13:00-14:40	Plenary Session 4: Novel Technologies Crystal Ballroom	16:15-16:40	Role of regulatory T cells in immuno-oncology Hiroyoshi Nishikawa, National Cancer Center, Chiba, Japan
	Session Cochairs: Seock-Ah Im, Seoul National University Hospital, Seoul, Korea, and William C. Hahn, Dana-Farber Cancer Institute, Boston, MA, USA	16:40-17:10	Spotlight on Proffered Papers Session 2
13:00-13:25	Computational inference of cancer	10.40-17.10	Crystal Ballroom
	dependencies in clinical samples Jung Kyoon Choi, KAIST, Daejeon, Korea		Session Cochairs: Jeeyun Lee, Sungkyunkwan University Samsung Medical Center, Seoul, Korea, and Sohrab Shah,
13:25-13:50	Lineage plasticity in prostate cancer Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA		Memorial Sloan Kettering Cancer Center, New York, NY, USA
13:50-14:15	Architecture of genomic rearrangements molding fusion oncogenes in lung adenocarcinomas Young Seok Ju, KAIST, Daejeon, Korea	16:40-16:50	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy* Joo Sang Lee, Cancer Data Science Lab, National Cancer Institute, National Institutes
14:15-14:40	Defining a cancer dependencies map William C. Hahn	16:50-17:00	of Health, Bethesda, MD, USA Myeloid-derived suppressor cells impair
14:40-15:00	Break	10.30 17.00	the antitumor activity of PD-1 blockade in gastric cancer* Woosook Kim, Columbia University, New York, NY, USA
15:00-16:40	Plenary Session 5: Immunology: Biomarkers and Therapies Crystal Ballroom	17:00-17:10	Humanized N-cadherin monoclonal antibodies demonstrate efficacy in treatment of castration-resistant prostate cancer*
	Session Cochairs: Hyunsook Lee, Seoul National University College of Natural Sciences, Seoul, Korea, and Zemin Zhang,		Evelyn Kono, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
	Peking University, Beijing, China	17:15-19:30	Poster Session B and Reception Sapphire Ballroom B

^{*}Short talk from proffered abstract

CONFERENCE PROGRAM AND SCHEDULE

SATURDAY	, NOVEMBER 17	10:40-11:05	Precision epigenetic cancer risk diagnosis taking account of our life Toshikazu Ushijima, National Cancer Center, Tokyo, Japan
07:30-08:30	Breakfast Crystal Ballroom Foyer	11:05-11:30	Targeting the histone lysine methyltransferase EZH2 in metastatic castrate-resistant prostate cancer Patrick Trojer
08:30-10:10	Plenary Session 6: Novel Targets Crystal Ballroom Session Cochairs: Young-Joon Surh, Seoul National University College of Pharmacy, Seoul, Korea, and Charles L. Sawyers,	11:30-11:55	Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma Bin Teh, National Cancer Center, Singapore
08:30-08:55	Memorial Sloan Kettering Cancer Center, New York, NY, USA Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study Byoung Chul Cho, Yonsei University College	11:55-12:20	Massively scaled single-cell whole-genome sequencing for studying cancer dynamics Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, NY, USA
08:55-09:20	of Medicine, Seoul, Korea Targeting MAT2A in MTAP-deleted cancers	12:20-14:00	Luncheon Symposium and Special Lecture
09:20-09:45	Katya Marjon, Agios Pharmaceuticals, Cambridge, MA, USA Using organoids to model, detect, and	12:20-13:00	Luncheon Symposium 7 Crystal Ballroom Presented by MSD
09.20-09.43	treat cancer Senthil K. Muthuswamy, Beth Israel Deaconess Medical Center, Boston, MA, USA		Session Chair: Dong-Wan Kim, Seoul University Hospital, Seoul, Korea The definition of "unprecedented":
09:45-10:10	Targeting DNA damage repair: PARP inhibitor and beyond Seock-Ah Im, Seoul National University College of Medicine, Seoul, Korea		Unheard of and unrivaled Alena Reznichenko, MSD, Asia-Pacific Medical Lead-NSCLC and New Indications, Singapore
10:10-10:40	Break	13:10-14:00	Special Lecture 3 Crystal Ballroom
			Session Chair: Sun Young Rha, Yonsei University College of Medicine, Seoul, Korea
10:40-12:20	Plenary Session 7: Epigenomics Crystal Ballroom Session Cochairs: Jin-Hyoung Kang, College of Medicine, The Catholic University of Korea, Seoul, Korea, and Patrick Trojer, Constellation Pharmaceuticals, Cambridge, MA, USA		Biomarker development strategy for pembrolizumab in GI tumors Mary J. Savage, MSD/Merck Research Lab, Kenilworth, NJ, USA

14:00-15:25 Plenary Session 8: Immunology:

Technologies and Innovations

Crystal Ballroom

Session Cochairs: Young-Joon Kim,

Yonsei University, Seoul, Korea and **Michel Sadelain,** Memorial Sloan Kettering Cancer

Center, New York, NY, USA

14:00-14:25 Immune profiling of B lymphocytes in the

era of cancer immunotherapy

Junho Chung, Seoul National University College of Medicine, Seoul, Korea

14:25-14:50 CAR therapy: The CD19 paradigm

and beyond Michel Sadelain

14:50-15:15 A personalized cancer vaccine targeting

neoepitopes

Chang-Yuil Kang, Seoul National University College of Pharmacy, Seoul, Korea

15:15-15:25 Multiplex three-dimensional imaging

cytometry for mapping tumor immune

 $microen vironment^*\\$

Steve Seung-Young Lee, University of Illinois

at Chicago, Chicago, IL, USA

15:25-15:30 Closing Remarks

Crystal Ballroom

Tae-You Kim, Seoul National University Hospital, Seoul, Korea

Charles L. Sawyers, Memorial Sloan

Kettering Cancer Center, New York, NY, USA

^{*}Short talk from proffered abstract